Tag: Mdr tb

According to the World Health Organization (WHO), directly observed treatment, short-course (DOTS) is a highly effective strategy for managing tuberculosis, with its success fundamentally dependent on a specific combination of first-line anti-TB drugs. This treatment approach, which ensures patients complete their full medication course under supervision, is crucial for preventing treatment failure and the spread of drug-resistant strains.

Kanamycin is an aminoglycoside antibiotic first isolated from the bacterium *Streptomyces kanamyceticus* in 1957 and historically used for various severe bacterial infections. Its usage has declined over time due to toxicity and resistance, but understanding what infections does kanamycin treat is key to appreciating its limited role today, particularly for multi-drug resistant tuberculosis (MDR-TB).

In 2023, an estimated 10.8 million people fell ill with tuberculosis (TB) worldwide, making it a leading cause of death from a single infectious agent [1.14.2]. The cornerstone of combating this global health issue is understanding **what are anti tubercular agents with examples**, the medications designed to treat infections caused by *Mycobacterium tuberculosis* [1.2.1, 1.14.2].

As the first new drug developed specifically for tuberculosis in over 40 years, bedaquiline represents a significant advancement in treating drug-resistant strains. While most patients are familiar with its oral tablet form, Sirturo, few understand its origin as bedaquiline BDQ drug powder—the critical active pharmaceutical ingredient (API) that must first be synthesized and purified before it can be formulated into a medicine. This review explores the nature of this essential raw material and its journey to becoming a potent clinical tool.

As of 2024, approximately half a million people globally are estimated to become ill with multidrug-resistant or rifampicin-resistant tuberculosis annually. This public health crisis has made the development of novel treatments critical, leading to the introduction of BDQ, or bedaquiline, a medication used to combat these stubborn infections.

According to the World Health Organization (WHO), over 10 million people fall ill with tuberculosis (TB) each year. BDQ, or bedaquiline, is a groundbreaking medication used as a cornerstone in the treatment of drug-resistant forms of this infectious disease, including multi-drug resistant (MDR-TB).